Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737

Cancer Research

Volumn 67, Issue 3, 2007, Pages 1176-1183

  Tahir, Stephen K ^a   Yang, Xiufen ^a   Anderson, Mark G ^a   Morgan Lappe, Susan E ^a   Sarthy, Aparna V ^a   Chen, Jun ^a   Warner, Robert B ^a   Ng, Shi Chung ^b   Fesik, Stephen W ^a   Elmore, Steve W ^a   Rosenberg, Saul H ^a   Tse, Christin ^a  

^a ABBOTT LABORATORIES   (United States)

^b LIGAND PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; BIM PROTEIN; CARBOPLATIN; ETOPOSIDE; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; PROTEIN NOXA;

ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EXPOSURE; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG SMALL CELL CANCER; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BIPHENYL COMPOUNDS; CARBOPLATIN; CARCINOMA, SMALL CELL; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DOWN-REGULATION; DRUG SYNERGISM; ETOPOSIDE; HUMANS; LUNG NEOPLASMS; MEMBRANE PROTEINS; NEOPLASM PROTEINS; NITROPHENOLS; PIPERAZINES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, SMALL INTERFERING; SULFONAMIDES; TRANSFECTION; UP-REGULATION;

EID: 33847061737     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-2203     Document Type: Article

References (42)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
2. Simon RG, Wagner H. Small cell lung cancer. Chest 2003;123:259-71s.
3. Kurup A, Hanna NH. Treatment of small cell lung cancer. Crit Rev Oncol Hematol 2004;52:117-26.
4. Stupp R, Monnerat C, Turrisi AT, Perry MC, Leyvraz S. Small cell lung cancer: state of the art and future perspectives. Lung Cancer 2004;45:105-17.
5. Okuno SH, Jett JR. Small cell lung cancer: current therapy and promising new regimens. Oncologist 2002;7:234-8.
6. Fennell DA. Bcl-2 as a target for overcoming chemoresistance in small-cell lung cancer. Clin Lung Cancer 2003;4:307-13.
7. Breton C, Story MD, Meyn RE. Bcl-2 expression correlates with apoptosis induction but not loss of clonogenic survival in small cell ling cancer cell lines treated with etoposide. Anticancer Drugs 1998;9:751-7.
8. Ohmori T, Podack ER, Nishio K, et al. Apoptosis of lung cancer cells caused by some anti-cancer agents (MMC, CPT-11, ADM) is inhibited by Bcl-2. Biochem Biophys Res Commun 1993;192:30-6.
9. Sartorius UA, Krammer PH. Upregulation of Bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines. Int J Cancer 2002;97:584-92.
10. Korsmeyer SJ. BCL-2 gene family and the regulation of programmed cell death. Cancer Res 1999;59:1963s-700s.
11. Cory S, Huang DCS, Adams JM. The Bcl-2 family: roles in cell survival and oncogenesis. Oncology 2003;22:8590-670.
12. Willis S, Day CL, Hinds MG, Huang DCS. The Bcl-2-regulated apoptotic pathway. J Cell Sci 2003;116:4053-6.
13. van Delft MF, Huang DCS. How the Bcl-2 family of proteins interact to regulate apoptosis. Cell Res 2006;16:203-13.
14. Cory S, Adams JM. The bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2002;2:647-56.
15. Adams JM, Cory S. Life-or-death decisions by the Bcl-2 protein family. Trends Biochem Sci 2001;26:61-6.
16. Degenhardt K, Sundararajan R, Lindsten T, Thompson C, White E. Bax and Bak independently promote cytochrome c release from mitochondria. J Biol Chem 2002;277:14127-34.
17. Letai A, Bassik MC, Walensky LD, et al. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2002;2:183-92.
18. Huang DCS, Strasser A. BH3-only proteins - essential initiators of apoptotic cell death. Cell 2000;103:839-42.
19. Chen L, Willis SN, Wei A, et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 2005;17:393-403.
20. Willis SN, Chen L, Dewson G, et al. Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev 2005;19:1294-305.
21. Labi V, Erlacher M, Kiessling S, Villunger A. BH3-only proteins in cell death initiation, malignant disease and anticancer therapy. Cell Death Differ 2006;13:1325-38.
22. Gélinas C, White E. BH3-only proteins in control: specificity regulates Mcl-1 and Bak-mediated apoptosis. Genes Dev 2006;19:1263-8.
23. Reed JC. Bcl-2: prevention of apoptosis as a mechanism of drug resistance. Hematol Oncol Clin North Am 1995;9:451-73.
24. Higashiyama M, Doi O, Kodama K, Yokouchi H, Tateishi R. Bcl-2 oncoprotein expression is increased especially in the portions of small cell carcinoma within the combined type of small cell lung cancer. Tumor Biol 1996;17:341-4.
25. Stefanaki K, Tzardi M, Kouvidou C, et al. Expression of p53, p21, mdm2, Rb, bax and Ki67 proteins in lymphomas of the mucosa-associated lymphoid (MALT) tissue. Anticancer Res 1998;18:2403-8.
26. Ikegaki N, Katsumata M, Minna J, Tsujimoto Y. Expression of bcl-2 in small cell lung carcinoma cells. Cancer Res 1994;54:6-8.
27. Kaiser U, Schilli M, Haag U, et al. Expression of bcl-2-profcein in small cell lung cancer. Lung Cancer 1996;15:31-40.
28. Jiang SX, Sato Y, Kuwao S, Kameya T. Expression of bcl-2 oncogene protein is prevalent in small cell lung carcinomas. J Pathol 1995;177:135-8.
29. Zhang YK, Fujita N, Tsuruo T. p21(waf1/cip1) acts in synergy with bcl-2 to confer multidrug resistance in a camptothecin-selected human lung-cancer cell line. Int J Cancer 1999;83:790-7.
30. Zangemeister-Wittke U, Schenker T, Luedke GH, Stahel RA. Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines. Br J Cancer 1998;78:1035-42.
31. Kitada S, Leone M, Sareth S, Zhai D, Reed JC, Pellecchia M. Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins. J Med Chem 2003;46:4259-64.
32. Shangary S, Johnson DE. Recent advances in the development of anticancer agents targeting cell death inhibitors in the Bcl-2 protein family. Leukemia 2003;17:1470-81.
33. Pulley H, Mohammad R. Small-molecule inhibitors of Bcl-2 protein. Drugs of the Future 2004;29:369-81.
34. Rubin CM, Kozloff M, Hoffman PC, et al. Phase 1 study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer. J Clin Oncol 2004;22:1110-7.
35. Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005;435-677-81.
36. Zhai D, Jin C, Satterthwait AC, Reed JC. Comparison of chemical inhibitors of antiapoptotic Bcl-2 family proteins. Cell Death Differ 2006;13:1419-21.
37. Tahir SK, Han EKH, Credo B, et al. A-204197, a new tubulin-binding agent with antimitotic activity in tumor cell lines resistant to known microtubule inhibitors. Cancer Res 2001;61:5480-5.
38. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
39. Harms K, Nozell S, Chen X. The common and distinct target genes of the p53 family transcription factors. Cell Mol Life Sci 2004;61:822-42.
40. Certo M, Del Gaizo Moore V, Nishino M, et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 2006;9:351-65.
41. Baldwin EL, Osheroff N. Etoposide, topoisomerase II and cancer. Curr Med Chem Anticancer Agents 2005;5:363-72.
42. Brabec V, Kasparkova J. Molecular aspects of resistance to antitumour or platinum drugs. Drug Resist Update 2002;5:147-61.